Intarcia's Once-Yearly Diabetes Drug Bests Januvia
This article was originally published in Scrip
Executive Summary
Will positive Phase III results for ITCA 650 versus Merck & Co.'s Januvia (sitagliptin) allow Intarcia Therapeutics to convince payers that its once- or twice-yearly diabetes medicine should be a first choice therapy for patients who fail to control their glucose with metformin?
You may also be interested in...
With $46m, i2o Takes Up The Challenge Of Winning Approval For ITCA 650
The Boston biotech raises series A cash and succeeds Intarcia as the sponsor of the GLP-1 drug/device combination product for type 2 diabetes, subject of two FDA complete response letters.
Intarcia Raises $215m As NDA For ITCA 650 Slips To Fourth Quarter
Intarcia announced $215m in new equity financing and revised its NDA submission timeline for the second time since it reported positive Phase III results for ITCA 650 versus Januvia in mid-2015.
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.